CD274 and non-small cell lung carcinoma: A retrospective cohort study of non-small cell lung cancer (NSCLC) patients showed that patients with high GSDME expression in tumor tissues exhibited better treatment responses to PD-L1 inhibitor combined with chemotherapy, with significantly improved objective response rate (ORR) and a median progression-free survival (PFS) of 18.20 months, markedly longer than that of the low GSDME expression group (6.70 months) (HR = 0.37, 95% CI: 0.14-0.97; P = 0.0371) (17).